1
|
Weiss C, Uziel O, Wolach O, Nordenberg J, Beery E, Bulvick S, Kanfer G, Cohen O, Ram R, Bakhanashvili M, Magen-Nativ H, Shilo N, Lahav M. Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo. Br J Cancer 2012; 107:1844-52. [PMID: 23169337 PMCID: PMC3504947 DOI: 10.1038/bjc.2012.460] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 09/12/2012] [Accepted: 09/12/2012] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND The importance of telomerase in multiple myeloma (MM) is well established; however, its response to bortezomib has not been addressed. METHODS The effect of bortezomib on telomerase activity and cell proliferation was evaluated in four MM cell lines and in myeloma cells obtained from eight patients. The mechanism of telomerase regulation on epigenetic, transcriptional, and post-translational levels was further assessed in two selected cell lines: ARP-1 and CAG. Clinical data were correlated with the laboratory findings. RESULTS Bortezomib downregulated telomerase activity and decreased proliferation in all cell lines and cells obtained from patients, albeit in two different patterns of kinetics. ARP-1 cells demonstrated higher and earlier sensitivity than CAG cells due to differential phosphorylation of hTERT by PKCα. Methylation of hTERT promoter was not affected. Transcription of hTERT was similarly inhibited in both lines by decreased binding of SP-1 and not of C-Myc and NFκB. The ex vivo results confirmed the in vitro findings and suggested existence of clinical relevance. CONCLUSION Bortezomib downregulates telomerase activity in MM cells both transcriptionally and post-translationally. MM cells, both in vitro and in patients, exhibit different sensitivity to the drug due to different post-translational response. The effect of bortezomib on telomerase activity may correlate with resistance to bortezomib in patients, suggesting its potential utility as a pre-treatment assessment.
Collapse
Affiliation(s)
- C Weiss
- Laniado Medical Center, Netanya, Israel
| | - O Uziel
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - O Wolach
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - J Nordenberg
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - E Beery
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - S Bulvick
- Laniado Medical Center, Netanya, Israel
| | - G Kanfer
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - O Cohen
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
| | - R Ram
- Institute of Hematology, Davidoff Cancer Center, Davidoff, Israel
- Internal Department A, Beilinson Hospital, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Peetah-Tikva 49100, Israel
| | - M Bakhanashvili
- Division of Infectious Diseases, Sheba Medical Center, Tel-Hashomer, Israel
| | - H Magen-Nativ
- Institute of Hematology, Davidoff Cancer Center, Davidoff, Israel
| | - N Shilo
- Internal Department A, Beilinson Hospital, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Peetah-Tikva 49100, Israel
| | - M Lahav
- Felsenstein Medical Research Center, Tel Aviv University, Tel Aviv, Israel
- Internal Department A, Beilinson Hospital, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Peetah-Tikva 49100, Israel
| |
Collapse
|
2
|
Barzilay E, Antonelli D, Bulvick S, Lev A, Gruzman C. [Non-cardiac pulmonary edema in a patient with recent cardiac pulmonary edema]. Minerva Med 1985; 76:1705-7. [PMID: 4047456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Pulmonary oedema may be cardiac or non-cardiac in origin: these two forms are clinically indistinguishable and their treatments are completely different. A case of pulmonary oedema is reported. This was believed to be of cardiac origin but did not respond to conventional treatment with diuretics and positive fibrotropic drugs. Insertion of a Swan-Ganz catheter revealed low capillary wedge on pressure. This, in turn, indicates that pulmonary oedema is non-cardiac in origin. The administration of liquids and cortisones led to a rapid improvement in the patient's condition. It is concluded that, whenever conventional treatment of pulmonary oedema fails, the possibility of non-cardiac oedema should be considered. In order to check this, capillary wedge pressure is measured.
Collapse
|